Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC64H84N10O14S2 |
InChIKeyLJOXSDPYCPKNON-NFVKYEHLSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United Kingdom | 10 Oct 2017 |